New drug target for hard-to-treat blood cancers enters early human testing
NCT ID NCT06179511
First seen Sep 30, 2025 · Last updated Apr 25, 2026 · Updated 30 times
Summary
This study tests an experimental drug called AZD9829 in 56 adults with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and to check for side effects. The drug is given through a vein, either alone or with other medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Melbourne, VIC 3000, Australia
-
Research Site
Tianjin, 300020, China
-
Research Site
Frankfurt, 60590, Germany
-
Research Site
Bologna, 40138, Italy
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Osaka, 545-8586, Japan
-
Research Site
Yoshida-gun, 910-1193, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Manchester, M204BX, United Kingdom
Conditions
Explore the condition pages connected to this study.